Mayne Pharma and PLIVA formed a strategic alliance to co-develop two major anticancer products – erythropoietin and granulocyte colony stimulating factor. PLIVA receives total net proceeds of €21 M from Mayne, which will receive exclusive commercialization rights for West Europe and other selected countries.